BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22899730)

  • 1. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.
    Phipps AI; Buchanan DD; Makar KW; Burnett-Hartman AN; Coghill AE; Passarelli MN; Baron JA; Ahnen DJ; Win AK; Potter JD; Newcomb PA
    Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1792-8. PubMed ID: 22899730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
    Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers.
    Phipps AI; Buchanan DD; Makar KW; Win AK; Baron JA; Lindor NM; Potter JD; Newcomb PA
    Br J Cancer; 2013 Apr; 108(8):1757-64. PubMed ID: 23511557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
    Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
    Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
    Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
    Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis.
    Hughes LA; Williamson EJ; van Engeland M; Jenkins MA; Giles GG; Hopper JL; Southey MC; Young JP; Buchanan DD; Walsh MD; van den Brandt PA; Alexandra Goldbohm R; Weijenberg MP; English DR
    Int J Epidemiol; 2012 Aug; 41(4):1060-72. PubMed ID: 22531127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer.
    Markovic S; Antic J; Dragicevic N; Hamelin R; Krivokapic Z
    J Mol Histol; 2012 Apr; 43(2):137-43. PubMed ID: 22210186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
    Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.
    Tran B; Kopetz S; Tie J; Gibbs P; Jiang ZQ; Lieu CH; Agarwal A; Maru DM; Sieber O; Desai J
    Cancer; 2011 Oct; 117(20):4623-32. PubMed ID: 21456008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
    Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
    BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes.
    Limsui D; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Harnack LJ; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
    J Natl Cancer Inst; 2010 Jul; 102(14):1012-22. PubMed ID: 20587792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
    Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia.
    Malesci A; Basso G; Bianchi P; Fini L; Grizzi F; Celesti G; Di Caro G; Delconte G; Dattola F; Repici A; Roncalli M; Montorsi M; Laghi L
    Br J Cancer; 2014 Mar; 110(5):1228-35. PubMed ID: 24434431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics.
    Hardikar S; Newcomb PA; Campbell PT; Win AK; Lindor NM; Buchanan DD; Makar KW; Jenkins MA; Potter JD; Phipps AI
    Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1130-7. PubMed ID: 25976417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.